@article{16b8797ee46444d49b096f02d0beec5e,
title = "Ibrutinib in the management of Waldenstrom macroglobulinemia.",
author = "Amir Yosef and Touloukian, \{Emily Z\} and Nambudiri, \{Vinod E\}",
note = "Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients who have failed treatment with other agents, has emerged as an important therapeutic agent in the management of Waldenstrom macroglobulinemia and other plasma cell dyscrasias.",
year = "2019",
month = mar,
day = "1",
doi = "10.1177/1078155218786037",
language = "American English",
volume = "25",
journal = "Journal of Oncology Pharmacy Practice",
number = "2",
}